Erik Frans Hensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erik Frans Hensen has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Jeroen C. Jansen
Department of Otolaryngology and Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands
17 shared publications - Olaf M. Neve
Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands
7 shared publications - Berit M. Verbist
Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
5 shared publications - Cas Smits
Department of Otolaryngology-Head and Neck Surgery, Ear and Hearing, Amsterdam Public Health Research Institute, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands
5 shared publications - Paul Merkus
Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam
5 shared publications - Peter Paul G. van Benthem
OtoBiology Leiden, Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands
5 shared publications
Latest Publications
- Open Access
- 25 May 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 175 (1) , 206-213
The Long‐Term Impact of Facial Palsy on the Quality of Life of Vestibular Schwannoma Patients
Objective: To compare long‐term quality of life (QoL) of vestibular schwannoma (VS) patients with and without facial palsy. Study design: Longitudinal cohort study. Setting: Tertiary referral centre. Methods: To assess QoL, VS patients completed the Penn Acoustic Quality of Life (PANQOL) questionnaire twice: at baseline and 6 years later. The results of patients with facial palsy were compared to those without. The effect of facial nerve function, sex and tumor size on PANQOL scores was assessed. Results: 484 patients completed the PANQOL. At baseline, 94% of patients had no or mild facial palsy and a mean PANQOL score of 71 out of 100 points (±18), while patients with moderate to severe palsy (6%) scored 61 points (±19). After 6 years, the PANQOL total scores remained relatively stable (70 and 57, respectively). In the multivariate analysis, the difference between patients without and with facial palsy was similar (PANQOL scores of 71 and 60, respectively). These differences do not exceed the predefined minimal clinically important difference (MCID) of 12.5 points. When focussing on questions related to facial function, differences are considerably larger (84 vs 41), exceeding the MCID. Conclusion: VS patients with facial palsy have lower mean total PANQOL scores than those without facial palsy, which remains on the long term. The difference did not exceed the MCID, which could suggest a limited impact of facial palsy on QoL, however, it may also point towards a limited sensitivity of the total PANQOL score for facial palsy‐related quality of life.
- 25 May 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 175 (1) , 206-213
Open AccessThe Long‐Term Impact of Facial Palsy on the Quality of Life of Vestibular Schwannoma Patients
Objective: To compare long‐term quality of life (QoL) of vestibular schwannoma (VS) patients with and without facial palsy. Study design: Longitudinal cohort study. Setting: Tertiary referral centre. Methods: To assess QoL, VS patients completed the Penn Acoustic Quality of Life (PANQOL) questionnaire twice: at baseline and 6 years later. The results of patients with facial palsy were compared to those without. The effect of facial nerve function, sex and tumor size on PANQOL scores was assessed. Results: 484 patients completed the PANQOL. At baseline, 94% of patients had no or mild facial palsy and a mean PANQOL score of 71 out of 100 points (±18), while patients with moderate to severe palsy (6%) scored 61 points (±19). After 6 years, the PANQOL total scores remained relatively stable (70 and 57, respectively). In the multivariate analysis, the difference between patients without and with facial palsy was similar (PANQOL scores of 71 and 60, respectively). These differences do not exceed the predefined minimal clinically important difference (MCID) of 12.5 points. When focussing on questions related to facial function, differences are considerably larger (84 vs 41), exceeding the MCID. Conclusion: VS patients with facial palsy have lower mean total PANQOL scores than those without facial palsy, which remains on the long term. The difference did not exceed the MCID, which could suggest a limited impact of facial palsy on QoL, however, it may also point towards a limited sensitivity of the total PANQOL score for facial palsy‐related quality of life.
- Open Access
- 6 January 2026
- Published by MDPI AG in Journal of Otorhinolaryngology, Hearing and Balance Medicine
- Vol. 7 (1) , 3
Comparing Methods for Uncertainty Estimation of Paraganglioma Growth Predictions
Background: Paragangliomas of the head and neck are rare, benign and indolent to slow-growing tumors. Not all tumors require immediate active intervention, and surveillance is a viable management strategy in a large proportion of cases. Treatment decisions are based on several tumor- and patient-related factors, with the tumor progression rate being a predominant determinant. Accurate prediction of tumor progression has the potential to significantly improve treatment decisions by helping to identify patients who are likely to require active treatment in the future. It furthermore enables better-informed timing for follow-up, allowing early intervention for those who will ultimately need it, and optimization of the use of resources (such as MRI scans). Crucial to this is having reliable estimates of the uncertainty associated with a future growth forecast, so that this can be taken into account in the decision-making process. Methods: For various tumor growth prediction models, two methods for uncertainty estimation were compared: a historical-based one and a Bayesian one. We also investigated how incorporating either tumor-specific or general estimates of auto-segmentation uncertainty impacts the results of growth prediction. The performance of the uncertainty estimates was examined both from a technical and a practical perspective. Study design: Method comparison study. Results: Data of 208 patients were used, comprising 311 paragangliomas and 1501 volume measurements, resulting in 2547 tumor growth predictions (a median of 10 predictions per tumor). As expected, the uncertainty increased with the length of the prediction horizon and decreased with the inclusion of more tumor measurement data in the prediction model. The historical method resulted in estimated confidence intervals where the actual value fell within the estimated 95% confidence interval 94% of the time. However, this method resulted in confidence intervals that were too wide to be clinically useful (often over 200% of the predicted volume), and showed poor ability to differentiate growing and stable tumors. The estimated confidence intervals of the Bayesian method were much narrower. However, the 95% credible intervals were too narrow, with the true tumor volume falling within them only 78% of the time, indicating underestimation of uncertainty and insufficient calibration. Despite this, the Bayesian method showed markedly better ability to distinguishing between growing and stable tumors, which has arguably the most practical value. When combining all growth models, the Bayesian method using tumor-specific auto-segmentation uncertainties resulted in an 86% correct classification of growing and non-growing tumors. Conclusions: Of the methods evaluated for predicting paraganglioma progression, the Bayesian method is the most useful in the considered context, because it shows the best ability to discriminate between growing and non-growing tumors. To determine how these methods could be used and what their value is for patients, they should be further evaluated in a clinical setting.
- 6 January 2026
- Published by MDPI AG in Journal of Otorhinolaryngology, Hearing and Balance Medicine
- Vol. 7 (1) , 3
Open AccessComparing Methods for Uncertainty Estimation of Paraganglioma Growth Predictions
Background: Paragangliomas of the head and neck are rare, benign and indolent to slow-growing tumors. Not all tumors require immediate active intervention, and surveillance is a viable management strategy in a large proportion of cases. Treatment decisions are based on several tumor- and patient-related factors, with the tumor progression rate being a predominant determinant. Accurate prediction of tumor progression has the potential to significantly improve treatment decisions by helping to identify patients who are likely to require active treatment in the future. It furthermore enables better-informed timing for follow-up, allowing early intervention for those who will ultimately need it, and optimization of the use of resources (such as MRI scans). Crucial to this is having reliable estimates of the uncertainty associated with a future growth forecast, so that this can be taken into account in the decision-making process. Methods: For various tumor growth prediction models, two methods for uncertainty estimation were compared: a historical-based one and a Bayesian one. We also investigated how incorporating either tumor-specific or general estimates of auto-segmentation uncertainty impacts the results of growth prediction. The performance of the uncertainty estimates was examined both from a technical and a practical perspective. Study design: Method comparison study. Results: Data of 208 patients were used, comprising 311 paragangliomas and 1501 volume measurements, resulting in 2547 tumor growth predictions (a median of 10 predictions per tumor). As expected, the uncertainty increased with the length of the prediction horizon and decreased with the inclusion of more tumor measurement data in the prediction model. The historical method resulted in estimated confidence intervals where the actual value fell within the estimated 95% confidence interval 94% of the time. However, this method resulted in confidence intervals that were too wide to be clinically useful (often over 200% of the predicted volume), and showed poor ability to differentiate growing and stable tumors. The estimated confidence intervals of the Bayesian method were much narrower. However, the 95% credible intervals were too narrow, with the true tumor volume falling within them only 78% of the time, indicating underestimation of uncertainty and insufficient calibration. Despite this, the Bayesian method showed markedly better ability to distinguishing between growing and stable tumors, which has arguably the most practical value. When combining all growth models, the Bayesian method using tumor-specific auto-segmentation uncertainties resulted in an 86% correct classification of growing and non-growing tumors. Conclusions: Of the methods evaluated for predicting paraganglioma progression, the Bayesian method is the most useful in the considered context, because it shows the best ability to discriminate between growing and non-growing tumors. To determine how these methods could be used and what their value is for patients, they should be further evaluated in a clinical setting.
- Open Access
- 13 November 2025
- Published by MDPI AG in Preprints.org
Comparing Methods for Uncertainty Estimation of Paraganglioma Growth Predictions
Background: Paragangliomas of the head and neck are rare, benign and indolent to slow-growing tumors. Not all tumors require immediate active intervention, and surveillance is a viable management strategy in a large proportion of cases. Treatment decisions are based on several tumor- and patient related factors, with the tumor progression rate being a predominant determinant. Accurate prediction of tumor progression has the potential to significantly improve treatment decisions, by helping to identify patients who are likely to require active treatment in the future. It furthermore enables better-informed timing for follow-up, allowing early intervention for those who will ultimately need it, and optimization of the use of resources (such as MRI scans). Crucial to this is having reliable estimates of the uncertainty associated with a future growth forecast, so that this can be taken into account in the decision-making process. Methods: For various tumor growth prediction models, two methods for uncertainty estimation were compared: a historical-based one and a Bayesian one. We also investigated how incorporating either tumor-specific or general estimates of auto-segmentation uncertainty impacts the results of growth prediction. The performance of uncertainty estimates was examined both from a technical and a practical perspective. Study design: Method comparison study. Results: Data of 208 patients were used, comprising 311 paragangliomas and 1501 volume measurements, resulting in 2547 tumor growth predictions (a median of 10 predictions per tumor). As expected, the uncertainty increased with the length of the prediction horizon and decreased with the inclusion of more tumor measurement data in the prediction model. The historical method resulted in estimated confidence intervals where the actual value fell within the estimated 95% confidence interval 94% of the time. However, this method resulted in confidence intervals that were too wide to be clinically useful (often over 200% of the predicted volume), and showed poor ability to differentiate growing and stable tumors. The estimated confidence intervals of the Bayesian method were much narrower. However, the tumor volume fell only 78% of the time within its estimated 95% confidence interval. Despite this, the Bayesian method showed good results for distinguishing between growing and stable tumors, which has arguably the most practical value. When combining all growth models, the Bayesian method that uses tumor-specific auto-segmentation uncertainties resulted in an 86% correct classification of growing and non-growing tumors. Conclusions: Of the methods evaluated for predicting paraganglioma progression, the Bayesian method is the most useful in the considered context, because it shows the best discrimination between growing and non-growing tumors. To determine how these methods could be used and what its value is for patients, they should be further evaluated in a clinical setting.
- 13 November 2025
- Published by MDPI AG in Preprints.org
Open AccessComparing Methods for Uncertainty Estimation of Paraganglioma Growth Predictions
Background: Paragangliomas of the head and neck are rare, benign and indolent to slow-growing tumors. Not all tumors require immediate active intervention, and surveillance is a viable management strategy in a large proportion of cases. Treatment decisions are based on several tumor- and patient related factors, with the tumor progression rate being a predominant determinant. Accurate prediction of tumor progression has the potential to significantly improve treatment decisions, by helping to identify patients who are likely to require active treatment in the future. It furthermore enables better-informed timing for follow-up, allowing early intervention for those who will ultimately need it, and optimization of the use of resources (such as MRI scans). Crucial to this is having reliable estimates of the uncertainty associated with a future growth forecast, so that this can be taken into account in the decision-making process. Methods: For various tumor growth prediction models, two methods for uncertainty estimation were compared: a historical-based one and a Bayesian one. We also investigated how incorporating either tumor-specific or general estimates of auto-segmentation uncertainty impacts the results of growth prediction. The performance of uncertainty estimates was examined both from a technical and a practical perspective. Study design: Method comparison study. Results: Data of 208 patients were used, comprising 311 paragangliomas and 1501 volume measurements, resulting in 2547 tumor growth predictions (a median of 10 predictions per tumor). As expected, the uncertainty increased with the length of the prediction horizon and decreased with the inclusion of more tumor measurement data in the prediction model. The historical method resulted in estimated confidence intervals where the actual value fell within the estimated 95% confidence interval 94% of the time. However, this method resulted in confidence intervals that were too wide to be clinically useful (often over 200% of the predicted volume), and showed poor ability to differentiate growing and stable tumors. The estimated confidence intervals of the Bayesian method were much narrower. However, the tumor volume fell only 78% of the time within its estimated 95% confidence interval. Despite this, the Bayesian method showed good results for distinguishing between growing and stable tumors, which has arguably the most practical value. When combining all growth models, the Bayesian method that uses tumor-specific auto-segmentation uncertainties resulted in an 86% correct classification of growing and non-growing tumors. Conclusions: Of the methods evaluated for predicting paraganglioma progression, the Bayesian method is the most useful in the considered context, because it shows the best discrimination between growing and non-growing tumors. To determine how these methods could be used and what its value is for patients, they should be further evaluated in a clinical setting.
- Open Access
- 16 October 2025
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 46 (10) , e519-e525
Vestibular Function and Complaints in Patients With Untreated Unilateral Vestibular Schwannoma
Objectives: The primary aim of this study is to assess the vestibular function of patients with an untreated unilateral vestibular schwannoma (VS) using multiple objective tests, and to correlate outcomes with vestibular complaints and QoL. The secondary aim is to evaluate patient and tumor characteristics that may affect objective and subjective vestibular function. Methods: In this prospective cross-sectional study, patients with untreated unilateral VS aged 18 years or older were included and evaluated using the caloric test, vHIT, cVEMP, DHI, PANQOL, and SF-36. Tumor and patient characteristics were retrieved from the patient files. Linear regression analyses were performed to identify predictors for vestibular function. Results: The majority (89%) showed one or more objective vestibular abnormalities. The lateral and anterior vHIT correlated with the caloric test results, hearing loss [ie, a lower gain is associated with a higher hearing threshold and thus more severe hearing impairment ( r =−0.57, P r =−0.41, P =0.003)]. However, no significant correlations between objective vestibular test results and vestibular complaints or quality of life were found. Tumor characteristics did not correlate with subjective outcomes (dizziness, quality of life). Even so, DHI scores showed a strong correlation with PANQOL scores (χ 2 =28.6, P <0.001). Conclusion: Vestibular complaints significantly impact the quality of life in vestibular schwannoma patients. Whereas vHIT does correlate with tumor size and hearing loss, neither objective vestibular function tests nor tumor characteristics correlate significantly with vestibular complaints or quality of life in this patient group.
- 16 October 2025
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 46 (10) , e519-e525
Open AccessVestibular Function and Complaints in Patients With Untreated Unilateral Vestibular Schwannoma
Objectives: The primary aim of this study is to assess the vestibular function of patients with an untreated unilateral vestibular schwannoma (VS) using multiple objective tests, and to correlate outcomes with vestibular complaints and QoL. The secondary aim is to evaluate patient and tumor characteristics that may affect objective and subjective vestibular function. Methods: In this prospective cross-sectional study, patients with untreated unilateral VS aged 18 years or older were included and evaluated using the caloric test, vHIT, cVEMP, DHI, PANQOL, and SF-36. Tumor and patient characteristics were retrieved from the patient files. Linear regression analyses were performed to identify predictors for vestibular function. Results: The majority (89%) showed one or more objective vestibular abnormalities. The lateral and anterior vHIT correlated with the caloric test results, hearing loss [ie, a lower gain is associated with a higher hearing threshold and thus more severe hearing impairment ( r =−0.57, P r =−0.41, P =0.003)]. However, no significant correlations between objective vestibular test results and vestibular complaints or quality of life were found. Tumor characteristics did not correlate with subjective outcomes (dizziness, quality of life). Even so, DHI scores showed a strong correlation with PANQOL scores (χ 2 =28.6, P <0.001). Conclusion: Vestibular complaints significantly impact the quality of life in vestibular schwannoma patients. Whereas vHIT does correlate with tumor size and hearing loss, neither objective vestibular function tests nor tumor characteristics correlate significantly with vestibular complaints or quality of life in this patient group.
- Open Access
Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review
Background/Objectives: NF2-related schwannomatosis (NF2) is a tumor predisposition syndrome that typically presents with bilateral vestibular schwannomas, together with other intracranial and spinal schwannomas, meningiomas, and/or ependymomas. Bevacizumab, a VEGF inhibitor, has the potential to decrease schwannoma volume and improve hearing in adults, but the literature on the effects in children is sparse. This narrative review aims to evaluate the use of bevacizumab in pediatric NF2 patients, focusing on hearing, tumor progression, and toxicity. Methods: A literature review was conducted following PRISMA guidelines. Articles were searched in PubMed, Embase, Web of Science, Cochrane Library, Emcare, and Academic Search Premier on 18 July 2024. Inclusion criteria were patients ≤ 18 years, diagnosed with NF2 and treated with bevacizumab. Two authors independently assessed the quality of the evidence and extracted relevant data from the included articles. Results: Seventeen articles including 62 pediatric NF2 patients met the inclusion criteria. Studies varied widely in treatment regimens and outcome parameters. Tumor regression was reported in 6/56 patients (11%) and 38/56 (68%) remained stable. Hearing improved in 15/45 patients (33%) and did not further deteriorate in 27/45 (60%). An improvement in other symptoms was seen in 6/29 patients (28%). Toxicity was reported in five studies, documenting 13 adverse events in 28 patients ranging from grade 1 to grade 3. Treatment was discontinued in both patients who experienced grade 3 toxicity. Conclusions: Bevacizumab seems to be a viable treatment option for pediatric NF2 patients. Tumor regression or stabilization is achieved in the majority of patients (77%). Moreover, a considerable number of pediatric patients experience hearing stabilization or improvement (93%). Bevacizumab appears to be relatively well tolerated, offering a non-invasive therapeutic option for children with NF2 suffering from progressive vestibular schwannomas and hearing loss.
Open AccessEfficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review
Background/Objectives: NF2-related schwannomatosis (NF2) is a tumor predisposition syndrome that typically presents with bilateral vestibular schwannomas, together with other intracranial and spinal schwannomas, meningiomas, and/or ependymomas. Bevacizumab, a VEGF inhibitor, has the potential to decrease schwannoma volume and improve hearing in adults, but the literature on the effects in children is sparse. This narrative review aims to evaluate the use of bevacizumab in pediatric NF2 patients, focusing on hearing, tumor progression, and toxicity. Methods: A literature review was conducted following PRISMA guidelines. Articles were searched in PubMed, Embase, Web of Science, Cochrane Library, Emcare, and Academic Search Premier on 18 July 2024. Inclusion criteria were patients ≤ 18 years, diagnosed with NF2 and treated with bevacizumab. Two authors independently assessed the quality of the evidence and extracted relevant data from the included articles. Results: Seventeen articles including 62 pediatric NF2 patients met the inclusion criteria. Studies varied widely in treatment regimens and outcome parameters. Tumor regression was reported in 6/56 patients (11%) and 38/56 (68%) remained stable. Hearing improved in 15/45 patients (33%) and did not further deteriorate in 27/45 (60%). An improvement in other symptoms was seen in 6/29 patients (28%). Toxicity was reported in five studies, documenting 13 adverse events in 28 patients ranging from grade 1 to grade 3. Treatment was discontinued in both patients who experienced grade 3 toxicity. Conclusions: Bevacizumab seems to be a viable treatment option for pediatric NF2 patients. Tumor regression or stabilization is achieved in the majority of patients (77%). Moreover, a considerable number of pediatric patients experience hearing stabilization or improvement (93%). Bevacizumab appears to be relatively well tolerated, offering a non-invasive therapeutic option for children with NF2 suffering from progressive vestibular schwannomas and hearing loss.
- Open Access
Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas
Background: Unilateral (uVS) and bilateral vestibular schwannoma (bVS) are distinct disease types, yet share tumorigenic features. This study examined causative genetic alterations in three groups: patients with NF2-related schwannomatosis (NF2), young patients with uVS (≤30 years), and older patients with uVS (≥40 years). Methods: Lymphocyte and vestibular schwannoma DNA was genetically analyzed. Outcomes included gene involvement, pathogenicity classification, variant type, effect, and location, and loss of heterozygosity (LOH) of chromosome 22. Results: Among 93 patients, 17% had NF2, 39% were ≤30 years with uVS, and 44% were ≥40 years with uVS. In all patients with NF2 (100%), two or more hits were detected in the tumor DNA, whereas patients with uVS had a slightly lower detection rate (89–98%). NF2-related tumors had a higher frequency of nucleotide variants (76%), while LOH events were more common in uVS (64–69%). Variants were mostly identified in NF2, with nonsense variants over-represented in patients with NF2 (38%) and frameshift variants more prevalent in uVS (44–51%). Conclusions: Biallelic NF2 inactivation primarily drives vestibular schwannoma tumorigenesis. In patients with NF2, two pathogenic NF2 variants or one NF2 variant with LOH are common, whereas patients with uVS often exhibit one NF2 variant with LOH. Additionally, variant types differ between patient groups.
Open AccessGenetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas
Background: Unilateral (uVS) and bilateral vestibular schwannoma (bVS) are distinct disease types, yet share tumorigenic features. This study examined causative genetic alterations in three groups: patients with NF2-related schwannomatosis (NF2), young patients with uVS (≤30 years), and older patients with uVS (≥40 years). Methods: Lymphocyte and vestibular schwannoma DNA was genetically analyzed. Outcomes included gene involvement, pathogenicity classification, variant type, effect, and location, and loss of heterozygosity (LOH) of chromosome 22. Results: Among 93 patients, 17% had NF2, 39% were ≤30 years with uVS, and 44% were ≥40 years with uVS. In all patients with NF2 (100%), two or more hits were detected in the tumor DNA, whereas patients with uVS had a slightly lower detection rate (89–98%). NF2-related tumors had a higher frequency of nucleotide variants (76%), while LOH events were more common in uVS (64–69%). Variants were mostly identified in NF2, with nonsense variants over-represented in patients with NF2 (38%) and frameshift variants more prevalent in uVS (44–51%). Conclusions: Biallelic NF2 inactivation primarily drives vestibular schwannoma tumorigenesis. In patients with NF2, two pathogenic NF2 variants or one NF2 variant with LOH are common, whereas patients with uVS often exhibit one NF2 variant with LOH. Additionally, variant types differ between patient groups.
- Open Access
- 26 April 2024
- Published by MDPI AG in Audiology Research
- Vol. 14 (3) , 401-411
Multi-Magnet Cochlear Implant Technology and Magnetic Resonance Imaging: The Safety Issue
Despite the spread of novel-generation cochlear-implant (CI) magnetic systems, access to magnetic resonance imaging (MRI) for CI recipients is still limited due to safety concerns. The aim of this study is to assess and record the experiences of Hires Ultra 3D (Advanced Bionics) recipients who underwent an MRI examination. A multicentric European survey about this topic was conducted focusing on safety issues, and the results were compared with the current literature. We collected a total of 65 MRI scans performed in 9 otologic referral centers for a total of 47 Hires Ultra 3D recipients, including, for the first time, 2 children and 3 teenagers. Preventive measures were represented by scanning time and sedation for children. Head wrapping was used in eight cases, and six of the eight cases received local anesthesia, even if both measures were not needed. Only three patients complained of pain (3/65 examinations, 4.6%) due to the tight head bandage, and one of the three cases required MRI scan interruption. No other adverse events were reported. We believe that these results should encourage MRI execution in accordance with manufacturer recommendations for Ultra 3D recipients.
- 26 April 2024
- Published by MDPI AG in Audiology Research
- Vol. 14 (3) , 401-411
Open AccessMulti-Magnet Cochlear Implant Technology and Magnetic Resonance Imaging: The Safety Issue
Despite the spread of novel-generation cochlear-implant (CI) magnetic systems, access to magnetic resonance imaging (MRI) for CI recipients is still limited due to safety concerns. The aim of this study is to assess and record the experiences of Hires Ultra 3D (Advanced Bionics) recipients who underwent an MRI examination. A multicentric European survey about this topic was conducted focusing on safety issues, and the results were compared with the current literature. We collected a total of 65 MRI scans performed in 9 otologic referral centers for a total of 47 Hires Ultra 3D recipients, including, for the first time, 2 children and 3 teenagers. Preventive measures were represented by scanning time and sedation for children. Head wrapping was used in eight cases, and six of the eight cases received local anesthesia, even if both measures were not needed. Only three patients complained of pain (3/65 examinations, 4.6%) due to the tight head bandage, and one of the three cases required MRI scan interruption. No other adverse events were reported. We believe that these results should encourage MRI execution in accordance with manufacturer recommendations for Ultra 3D recipients.
- Open Access
Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience
(1) Background: NF2-related schwannomatosis, characterized by the development of bilateral vestibular schwannomas, often necessitates varied treatment approaches. Bevacizumab, though widely utilized, demonstrates variable effectiveness on hearing and tumor growth. At the same time, (serious) adverse events have been frequently reported. (2) Methods: A single center retrospective study was conducted, on NF2-related schwannomatosis patients treated with bevacizumab from 2013 to 2023, with the aim to assess treatment-related and clinical outcomes. Outcomes of interest comprised hearing, radiologic response, symptoms, and adverse events. (3) Results: Seventeen patients received 7.5 mg/kg bevacizumab for 7.1 months. Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss. Vestibular schwannoma regression occurred in 31%, and 69% remained stable. Further symptomatic improvement was reported by 41%, stable symptoms by 47%, and worsened symptoms by 12%. Treatment discontinuation due to adverse events was observed in 29% of cases. Hypertension (82%) and fatigue (29%) were most frequently reported, with no occurrences of grade 4/5 toxicities. (4) Conclusion: Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms in NF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted.
Open AccessBevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience
(1) Background: NF2-related schwannomatosis, characterized by the development of bilateral vestibular schwannomas, often necessitates varied treatment approaches. Bevacizumab, though widely utilized, demonstrates variable effectiveness on hearing and tumor growth. At the same time, (serious) adverse events have been frequently reported. (2) Methods: A single center retrospective study was conducted, on NF2-related schwannomatosis patients treated with bevacizumab from 2013 to 2023, with the aim to assess treatment-related and clinical outcomes. Outcomes of interest comprised hearing, radiologic response, symptoms, and adverse events. (3) Results: Seventeen patients received 7.5 mg/kg bevacizumab for 7.1 months. Following treatment, 40% of the patients experienced hearing improvement, 53%, stable hearing, and 7%, hearing loss. Vestibular schwannoma regression occurred in 31%, and 69% remained stable. Further symptomatic improvement was reported by 41%, stable symptoms by 47%, and worsened symptoms by 12%. Treatment discontinuation due to adverse events was observed in 29% of cases. Hypertension (82%) and fatigue (29%) were most frequently reported, with no occurrences of grade 4/5 toxicities. (4) Conclusion: Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms in NF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted.
- Open Access
- 20 March 2024
- Published by Wiley in Case Reports in Otolaryngology
- Vol. 2024, 1-7
SDHAF2-Linked Metastatic Paraganglioma: A Case Report with Implications for Counseling and Follow-Up of Pathogenic SDHAF2 Variant Carriers
Head and neck paragangliomas are slow growing and highly vascular neuroendocrine tumors. It is currently assumed that SDHAF2 variants exclusively cause benign and often multicentric head and neck paragangliomas. Here, we present a patient diagnosed with multiple SDHAF2-linked head and neck paragangliomas who in addition developed paraganglioma metastases to the lung and spine and a primary or metastatic paraganglioma in the head of the pancreas. During the course of the disease, a range of management strategies were deployed for the different head and neck tumors, including total resections, partial resections, and active surveillance. After identification of the paraganglioma metastases, the patient was treated with lanreotide after which the disease remained stable during the 27months of follow-up.
- 20 March 2024
- Published by Wiley in Case Reports in Otolaryngology
- Vol. 2024, 1-7
Open AccessSDHAF2-Linked Metastatic Paraganglioma: A Case Report with Implications for Counseling and Follow-Up of Pathogenic SDHAF2 Variant Carriers
Head and neck paragangliomas are slow growing and highly vascular neuroendocrine tumors. It is currently assumed that SDHAF2 variants exclusively cause benign and often multicentric head and neck paragangliomas. Here, we present a patient diagnosed with multiple SDHAF2-linked head and neck paragangliomas who in addition developed paraganglioma metastases to the lung and spine and a primary or metastatic paraganglioma in the head of the pancreas. During the course of the disease, a range of management strategies were deployed for the different head and neck tumors, including total resections, partial resections, and active surveillance. After identification of the paraganglioma metastases, the patient was treated with lanreotide after which the disease remained stable during the 27months of follow-up.
- Open Access
- 28 November 2023
- Published by Machine Learning for Biomedical Imaging in Machine Learning for Biomedical Imaging
- Vol. 2 (Generative) , 657-685
CoNeS: Conditional neural fields with shift modulation for multi-sequence MRI translation
Multi-sequence magnetic resonance imaging (MRI) has found wide applications in both modern clinical studies and deep learning research. However, in clinical practice, it frequently occurs that one or more of the MRI sequences are missing due to different image acquisition protocols or contrast agent contraindications of patients, limiting the utilization of deep learning models trained on multi-sequence data. One promising approach is to leverage generative models to synthesize the missing sequences, which can serve as a surrogate acquisition. State-of-the-art methods tackling this problem are based on convolutional neural networks (CNN) which usually suffer from spectral biases, resulting in poor reconstruction of high-frequency fine details. In this paper, we propose Conditional Neural fields with Shift modulation (CoNeS), a model that takes voxel coordinates as input and learns a representation of the target images for multi-sequence MRI translation. The proposed model uses a multi-layer perceptron (MLP) instead of a CNN as the decoder for pixel-to-pixel mapping. Hence, each target image is represented as a neural field that is conditioned on the source image via shift modulation with a learned latent code. Experiments on BraTS 2018 and an in-house clinical dataset of vestibular schwannoma patients showed that the proposed method outperformed state-of-the-art methods for multi-sequence MRI translation both visually and quantitatively. Moreover, we conducted spectral analysis, showing that CoNeS was able to overcome the spectral bias issue common in conventional CNN models. To further evaluate the usage of synthesized images in clinical downstream tasks, we tested a segmentation network using the synthesized images at inference. The results showed that CoNeS improved the segmentation performance when some MRI sequences were missing and outperformed other synthesis models. We concluded that neural fields are a promising technique for multi-sequence MRI translation.
- 28 November 2023
- Published by Machine Learning for Biomedical Imaging in Machine Learning for Biomedical Imaging
- Vol. 2 (Generative) , 657-685
Open AccessCoNeS: Conditional neural fields with shift modulation for multi-sequence MRI translation
Multi-sequence magnetic resonance imaging (MRI) has found wide applications in both modern clinical studies and deep learning research. However, in clinical practice, it frequently occurs that one or more of the MRI sequences are missing due to different image acquisition protocols or contrast agent contraindications of patients, limiting the utilization of deep learning models trained on multi-sequence data. One promising approach is to leverage generative models to synthesize the missing sequences, which can serve as a surrogate acquisition. State-of-the-art methods tackling this problem are based on convolutional neural networks (CNN) which usually suffer from spectral biases, resulting in poor reconstruction of high-frequency fine details. In this paper, we propose Conditional Neural fields with Shift modulation (CoNeS), a model that takes voxel coordinates as input and learns a representation of the target images for multi-sequence MRI translation. The proposed model uses a multi-layer perceptron (MLP) instead of a CNN as the decoder for pixel-to-pixel mapping. Hence, each target image is represented as a neural field that is conditioned on the source image via shift modulation with a learned latent code. Experiments on BraTS 2018 and an in-house clinical dataset of vestibular schwannoma patients showed that the proposed method outperformed state-of-the-art methods for multi-sequence MRI translation both visually and quantitatively. Moreover, we conducted spectral analysis, showing that CoNeS was able to overcome the spectral bias issue common in conventional CNN models. To further evaluate the usage of synthesized images in clinical downstream tasks, we tested a segmentation network using the synthesized images at inference. The results showed that CoNeS improved the segmentation performance when some MRI sequences were missing and outperformed other synthesis models. We concluded that neural fields are a promising technique for multi-sequence MRI translation.